Virica Biotech Inc. announced it will collaborate with Oxford Biomedica plc to improve the yield and production efficiency of Oxford Biomedica's next generation lentiviral vector gene therapies using Virica's Viral Sensitizers (VSEs™). Oxford Biomedica is a pioneer of cell and gene therapies. Its LentiVector® platform enables the successful development of breakthrough gene and cell-based medicines, and through collaborations with pharmaceutical partners, has delivered the first FDA and EMA approved CAR-T cell therapy.